Featured Research

from universities, journals, and other organizations

Potential Treatment For Intracerebral Hemorrhage Under Study

Date:
January 20, 2006
Source:
Medical College of Georgia
Summary:
The first potential treatment for strokes that result from bleeding in the brain is under study at the Medical College of Georgia. MCG is one of about 100 sites worldwide looking at whether patients with this type of stroke – often resulting from the rupture of fragile arteries branching off the main arteries of the brain – can benefit from rapid delivery of a factor that is part of the body’s natural clotting process.

Dr. Christiana E. Hall, MCG neurologist, and Dr. Jeffrey Switzer, vascular neurology fellow.
Credit: Photo by Phil Jones

The first potential treatment for strokes that result from bleeding in the brain is under study at the Medical College of Georgia.

MCG is one of about 100 sites worldwide looking at whether patients with this type of stroke – often resulting from the rupture of fragile arteries branching off the main arteries of the brain – can benefit from rapid delivery of a factor that is part of the body’s natural clotting process.

Intracerebral hemorrhage accounts for up to 15 percent of the 750,000 strokes that occur annually in the United States, says Dr. Christiana E. Hall, MCG neurologist and a principal investigator on the NovoSeven® study.

“The biggest risk factor for these hemorrhages is hypertension, which we have a big problem with in the South,” says Dr. Hall. “We are seeing young men and women in their 40s come in with these types of strokes when it’s usually a disease of those 60 and older. These are mothers and fathers with children they are raising and they have this life-altering or lethal condition just come out of the blue.

“What we think happens, in the setting of long-standing untreated hypertension, is very small penetrating vessels in the deep parts of the brain that are bombarded with high pressures undergo changes. They thicken, develop tiny little out-pouches that destabilize them and make them weaker. Then one day one of these tiny penetrators just gives out and bleeds into the brain tissue,” she says.

The bleeding essentially stretches and tears brain tissue, irreparably dissecting vital communication structures between brain cells. “It can disrupt huge bundles of fibers that carry information,” says Dr. Hall. “Modern neuroimaging shows it also seems to have an effect more distant than just where you see the hemorrhage.”

Patients can experience one-sided paralysis; coma; locked-in syndrome where they are fully conscious but paralyzed from the eyes down; or death as the blood spreads into brain tissue. Without treatment, bleeding and destruction may continue for several hours.

Treatment efforts to date, including medical therapies such as other clotting agents and surgery, generally haven’t improved outcomes, Dr. Hall says. She hopes NovoSeven®, or recombinant activated factor VIIa, will.

Activated factor VIIa is a substance certain hemophilia patients may not have enough of. In fact the Food and Drug Administration has approved it for hemophiliacs who develop antibodies to other treatments, Dr. Hall says. It looks promising for intracerebral hemorrhage patients as well because it works at sites where there is tissue factor, which is exposed at sites of blood vessel injury.

Much like tissue plasminogen activator, or tPA, the first drug FDA approved to treat clot-based or ischemic strokes, activated factor VIIa for hemorrhage needs to be given as soon as possible after the onset of symptoms to minimize damage and maximize recovery, Dr. Hall says.

“We know that nearly 40% of these hemorrhages continue to grow and may grow significantly larger during the early hours after they start,” she says. “The larger the hemorrhage, the more life-threatening or disabling it becomes. The whole idea behind the study is to intervene early to stop bleeding, halt hemorrhage growth, and thus make possible better outcomes.”

The study protocol requires that patients receive a computerized tomography scan within three hours after symptom onset. Symptoms include sudden problems with weakness, particularly on one side of the body; confusion or trouble talking or comprehending; difficulty seeing out of one or both eyes; trouble with balance and coordination; and severe headaches.

After the CT scan helps determine the source and size of the hemorrhage, the stroke team has an hour to infuse the liquid that team members hope will stop the damage. “We understand that every minute this hemorrhage may be expanding so we will give the treatment at the earliest possible moment,” Dr. Hall says.

One day after treatment, a second CT scan shows the final size of the hemorrhage at 24 hours and helps document how the drug worked. Blood samples also are taken and neurological exams, are performed.

MCG Medical Center receives about one to two patients per week with the type of stroke that could qualify for the study, she says. The MCG stroke team also is able to help treat patients at eight hospitals in rural Georgia via an Internet-based examination system developed at MCG. Patients with hemorrhage evaluated at those remote sites also will be considered for the study but will need to be rapidly transported to MCG to receive the drug, Dr. Hall says. Currently the MCG team works with health care providers at the distant hospitals to give tPA.

The study, comparing two doses of activated factor VIIa to placebo, will enroll 675 patients worldwide. Patients must be 18 or older and have a primary hemorrhage of almost any size and location. However, those who present with poor neurological exams, such as those already in a coma, cannot be enrolled.

“It’s not the final answer but it’s a first step,” Dr. Hall says. “If it’s successful, this is going to be the first treatment for any aspect of intracerebral hemorrhage that has ever been shown to make a difference for these patients.”


Story Source:

The above story is based on materials provided by Medical College of Georgia. Note: Materials may be edited for content and length.


Cite This Page:

Medical College of Georgia. "Potential Treatment For Intracerebral Hemorrhage Under Study." ScienceDaily. ScienceDaily, 20 January 2006. <www.sciencedaily.com/releases/2006/01/060118092701.htm>.
Medical College of Georgia. (2006, January 20). Potential Treatment For Intracerebral Hemorrhage Under Study. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2006/01/060118092701.htm
Medical College of Georgia. "Potential Treatment For Intracerebral Hemorrhage Under Study." ScienceDaily. www.sciencedaily.com/releases/2006/01/060118092701.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins